[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mucosal-cytokine-profile-of-patients-type-i-and-iii-interferons-pro-inflammatory-cytokines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mucosal-cytokine-profile-of-patients-type-i-and-iii-interferons-pro-inflammatory-cytokines":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100053566",false,"NCT07698769","ENVIEANCILLAIRE: Efficacy of Nirsevimab in Children Hospitalised With RSV Bronchiolitis - A Subsidiary Study on the Immune Signature and Microbial Environment","ENVIEANCILLAIR","Inclusion Criteria:\n\n* Written consent to take part in the study\n* Registered with a social security scheme\n\nCases:\n\n* Children aged 6 months or under included in the ENVIE study. Treated for bronchiolitis caused by RSV\n* Admitted to hospital following a visit to the paediatric A\\&E department\n\nControl group:\n\nChildren aged 6 months or under included in the ENVIE study. Admitted to a standard ward or a Short-Stay Unit, or having attended the paediatric A\\&E department\n\nFor one of the following reasons:\n\n* Febrile urinary tract infection, without acute ENT or respiratory symptoms\n* Acute gastroenteritis, without acute ENT or respiratory symptoms\n* Infant colic without fever, without ENT or acute respiratory condition\n* Weight stagnation or feeding difficulties without fever, without acute ENT or respiratory symptoms\n* Neonatal jaundice without fever, without acute ENT or respiratory symptoms\n* Unexplained crying without fever, without acute ENT or respiratory symptoms\n* Head injury, without acute ENT or respiratory symptoms\n* Admitted for acute surgical conditions, without fever, without acute ENT or respiratory symptoms\n* Nappy rash, without fever, without acute ENT or respiratory symptoms\n* Fracture, without fever, without acute ENT or respiratory symptoms.\n\nExclusion Criteria:\n\n* Refusal to participate by the legal representative\n* Administration of palivizumab\n* Maternal vaccination against RSV.","ALL","0 Months","6 Months",{"count":19,"type":20},110,"ESTIMATED","OBSERVATIONAL","Among children aged ≤ 6 months included in the ENVIE study, the ENVIE\\_ancillaire study will be offered to cases of RSV infection or to controls. The study involves a nasopharyngeal swab using a FLOQ-SWAB™ swab and a fingertip sample (dextro type). These samples will be collected specifically for the purpose of studying immunity.\n\nA blood sample may also be requested for children weighing ≥5 kg who are included in the ENVIE\\_ancillaire study. The purpose of this sample collection will be to conduct an advanced immunological study",[24],"Mucosal Cytokine Profile of Patients (Type I and III Interferons, Pro-inflammatory Cytokines)","RECRUITING","2026-07-07",{"date":28,"type":29},"2026-07-13","ACTUAL",{"date":31,"type":29},"2024-12-05",{"date":33,"type":20},"2026-12-05",{"name":35,"class":36},"Centre Hospitalier Intercommunal Creteil","OTHER",3,""]